www.bloomberg.com
A group of former FDA leaders are criticizing the agency’s new vaccine approval approach, arguing it deviates from established regulatory standards and potentially endangers public health. Their concerns center around the loosening of traditional requirements for vaccine approval, suggesting this shift prioritizes speed over rigorous safety and efficacy evaluation. They believe this revised philosophy could compromise the health and safety of Americans who rely on the FDA’s robust vetting processes.
